Diagnosis Segment to Dominate Acute Pancreatitis During 2022–2030
According to our new research study on "Acute Pancreatitis Market Size and Forecasts (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis," the acute pancreatitis market size is expected to grow from US$ 5,649.77 million in 2022 and is expected to reach a value of US$ 8,827.37 million by 2030; it is anticipated to record a CAGR of 5.7% from 2022 to 2030. Key factors driving the acute pancreatitis market growth include a rise in pancreatic cancer cases due to acute pancreatitis and rising incidences of diabetes following acute pancreatitis. However, side effects of pancreatitis and pancreatic cancer treatments hinders the acute pancreatitis market growth.
Acute pancreatitis may cause pancreatic cancer as it is an early symptom of pancreatic cancer; nearly 1% of acute pancreatitis admissions result in positive pancreatic cancer diagnoses. It takes several months for these patients to be diagnosed with pancreatic cancer after acute pancreatitis is diagnosed, but some suffer longer diagnostic delays due to initial misdiagnosis, which may hinder their recovery. Recurrent occurrence of acute pancreatitis leads to chronic pancreatitis, which may further increase the risk of pancreatic cancer.
Acute Pancreatitis Market Analysis, by Geography, 2022 (%)
Source: The Insight Partners Analysis
According to the National Institute of Diabetes and Digestive and Kidney Diseases, acute pancreatitis leads to ~275,000 hospital admissions each year, and this number has been increasing in the US. ~35–40% of acute pancreatitis cases in the US are due to gallstones, while alcohol consumption is the cause of 30% of cases. Pancreatitis is usually mild in 80% of patients who are admitted, and most can be discharged within a few days of their hospitalization. The mortality rate of acute pancreatitis is ~2%, and the disease has a relapse rate of 0.6–5.6%. Alcohol-related pancreatitis has the highest rate of relapse. According to an article published in Lancet Gastroenterology Hepatology in 2022, the global pooled incidence of acute pancreatitis is 34 cases per 100,000 per year. North America has 58.2 cases per 100,000 people per year (the US has 58.2 cases per 100,000 people per year). In Europe, Sweden and Denmark record 24.7 and 15.0 cases of acute pancreatitis per 100,000 people, respectively. Therefore, the rising number of pancreatic cancer cases due to acute pancreatitis boosts the growth of the acute pancreatitis market.
Abbott Laboratories, GE HealthCare Technologies Inc, Samsung Healthcare, Koninklijke Philips NV, Baxter International Inc, Dynavax Technologies Corp, Actim Oy, Medtronic Plc, Boston Scientific Corp, and Fresenius Kabi AG are among the key companies operating in the acute pancreatitis market. The companies have been implementing various strategies that contributed to their growth and led to various changes in the market. Market players have been adopting both organic (such as launches, expansion, and product approvals) and inorganic strategies (such as product launches, partnerships, and collaborations) or secure growth.
In March 2022, Fresenius Kabi closed the acquisition of Ivenix, Inc. (“Ivenix”), a specialized infusion therapy company. Ivenix adds a next-generation infusion therapy platform to Fresenius Kabi’s portfolio for the significant US market, which provides the company with key capabilities in hospital connectivity and interoperability. The combination of Ivenix’ leading hardware and software products with Fresenius Kabi’s intravenous fluids and infusion devices would allow them to create a comprehensive and leading setup of premium products. With such developments, both these companies have taken steps toward achieving sustainable growth in the high-value MedTech space.
The report segments the acute pancreatitis market as follows:
The acute pancreatitis market, by offerings, is segmented into medication, diagnosis, and others. In 2022, the diagnosis segment held the largest share of the market. The others segment is expected to record the highest CAGR during 2022-2030. The acute pancreatitis market, by causes, is segmented into gallstones, alcoholism, genetic disorders, infection, and others. In 2022, the gallstones segment held the largest share of the market. Moreover, market for the same segment is expected to grow at the fastest CAGR during 2022-2030. The acute pancreatitis market, by end user, is segmented into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. In 2022, the hospitals segment held the largest share of the market. However, the diagnostic laboratories segment is estimated to record the highest CAGR during 2022-2030.
Based on geography, the acute pancreatitis market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Email Id: firstname.lastname@example.org